New lupus drug candidate enters first human tests

NCT ID NCT07011043

Recruiting now Disease control Sponsor: Climb Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called budoprutug (TNT119) in 30 adults with active systemic lupus erythematosus (SLE). The main goal is to check the drug's safety and how the body processes it. Participants will receive a single dose of the drug by IV, and researchers will monitor them for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: budoprutug (TNT119)
What this could lead to: If this drug is safe and shows promise, it could lead to a new treatment option for people with active lupus who haven't responded well to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, focused mainly on safety. It is too small and early to know if the drug will effectively treat lupus or have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Climb Bio Investigative Site #100101
RECRUITING

San Antonio, Texas, 78215, United States
Climb Bio Investigative Site #100103
RECRUITING

Caguas, Puerto Rico
Climb Bio Investigative Site #100104
RECRUITING

Allen, Texas, 75013, United States
Climb Bio Investigative Site #380101
RECRUITING

Ternopil, Ukraine
Climb Bio Investigative Site #380102
RECRUITING

Ivano-Frankivsk, Ukraine
Climb Bio Investigative Site #380103
RECRUITING

Kyiv, Ukraine
Climb Bio Investigative Site #380104
RECRUITING

Vinnytsia, Ukraine
Climb Bio Investigative Site #380105
RECRUITING

Vinnytsia, Ukraine
Climb Bio Investigative Site #380106
RECRUITING

Kyiv, Ukraine
Climb Bio Investigative Site #995101
RECRUITING

Tbilisi, 0141, Georgia
Climb Bio Investigative Site #995102
RECRUITING

Tbilisi, 0112, Georgia
Climb Bio Investigative Site# 300102
RECRUITING

Exochi, Thessaloniki, 57010, Greece
Climb Bio Investigative Site# 300103
RECRUITING

Thessaloniki, Thessaloniki, 54642, Greece
Climb Bio Investigative Site# 340101
RECRUITING

Sabadell, Barcelona, 08208, Spain
Climb Bio Investigative Site# 340102
RECRUITING

A Coruña, 15006, Spain
Climb Bio Investigative Site# 359101
RECRUITING

Plovdiv, 4002, Bulgaria
Climb Bio Investigative Site# 359102
RECRUITING

Sofia, 1618, Bulgaria
Climb Bio Investigative Site# 400101
RECRUITING

Cluj-Napoca, 400006, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.